Does biomedicine entail the successful reduction of pathology to biology?

Perspectives in Biology and Medicine

Volumn 47, Issue 3, 2004, Pages 357-371

  Keating, Peter ^a   Cambrosio, Alberto ^b  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGY; BIOMEDICINE; CELL DIFFERENTIATION; HUMAN; IMMUNOCOMPETENT CELL; LEUKEMIA CELL; MEDICAL RESEARCH; PHILOSOPHY; PRIORITY JOURNAL; REDUCTION; REVIEW;

EID: 3042836117     PISSN: 00315982     EISSN: None     Source Type: Journal    
DOI: 10.1353/pbm.2004.0040     Document Type: Review

References (43)

1. Ahrens, E. H. 1992. The crisis in clinical research: Overcoming institutional obstacles. New York: Oxford Univ. Press.
2. Ayton, P. M., and M. L. Cleary. 2001. Molecular mechanisms of leukemogenesis mediated by MLL fusion proteins. Oncogene 20:5695-707.
3. Benaroyo, L. 1997. La renaissance de la pensée biologique de Rudolf Virchow dans l'oeuvre de Ludwig Aschoff. Rev Hist Sci (Paris) 50:447-60.
4. Bonah, C. 1998. Pathological anatomy versus pathological physiology: A Franco-German dispute over a province for pathology. In Pathology in the 19th and 20th centuries: The relation between theory and practice, ed C.-R. Pruell, 31-53. Sheffield: European Association for the History of Medicine and Health Publications.
5. Booth, C. C. 1993. Clinical research. In Companion encyclopedia of the history of medicine, vol. 1, ed. W. F. Bynum and R. Porter, 205-29. London: Routledge.
6. Canguilhem, G. 1943. Essai sur quelques problèmes concernant le normal et le pathologique. Strasbourg: Comité des Publications de la Faculté des Lettres de Strasbourg.
7. Dill, K. A. 1999. Strengthening biomedicine's roots. Nature 400:309-10.
8. Escobar, M. R. 1989. Oncogenic viruses. In The pathobiology of neoplasia, ed. A. E. Sirica, 81-109. New York: Plenum Press.
9. Gaudillière, J.-P. 2002. Inventer la biomédecine: La France, l'Amérique et la production des savoirs du vivant (1945-1965). Paris: La Découverte.
10. Greaves, M. F. 1982. "Target" cells, cellular phenotypes, and lineage fidelity in human leukaemia. J Cell Physiol Supp 1:113-15.
11. Greaves, M. F., et al. 1981. Exploitation of monoclonal antibodies: A "who's who" of haematopoietic malignancy. Blood Cells 7:257-80.
12. Greaves, M. F., et al. 1986. Lineage promiscuity in hemopoietic differentiation and leukemia. Blood 67:1-11.
13. Grignani, F., et al. 2000. PML/RAR alpha fusion protein expression in normal hematopoietic progenitors dictates myeloid commitment and the promyelocytic phenotype. Blood 96:1531-37.
14. Hull, D. L., and M. H. V. Van Regenmortel. 2002. Introduction. In Promises and limits of reductionism in the biomedical sciences, ed. M. H. V. Van Regenmortel and D. L. Hull, 1-10. New York: John Wiley.
15. Janossy G., et al. 1978. Use of the fluorescence activated cell sorter in human leukaemia. In Immunofluorescence and related staining techniques, ed. W. Knapp, K. Holubar, and G. Wick, 111-22. Elsevier: North-Holland Biomedical Press.
16. Kajita, A. 1983. Rudolf Virchow and his successors. In History of pathology, ed. T. Ogawa, 163-84. Osaka: Taniguchi Foundation.
17. Keating, P., and A. Cambrosio. 2001. The new genetics and cancer: The contributions of clinical medicine in the era of biomedicine. J Hist Med Allied Sci 56:321-52.
18. Keating, P., and A. Cambrosio. 2003. Biomedical platforms: Realigning the normal and the pathological in late-twentieth-century medicine. Cambridge: MIT Press.
19. Keel, O. 1980. La pathologie tissulaire de John Hunter. Gesnerus 37:47-61.
20. Laubichler, M. D., and G. P. Wagner. 2001. How molecular is molecular developmental biology? A reply to Alex Rosenberg's reductionism redux: computing the embryo. Biol Philos 16:53-68.
21. Lawrence, C. 1997. Clinical research. In Science in the twentieth century, ed. J. Krige and D. Pestre, 439-59. Amsterdam: Harwood Academic.
22. Lenoir, T. 1988. Science for the clinic: Science policy and the formation of Carl Ludwigs institute in Leipzig. In The investigative enterprise: Experimental physiology in nineteenth-century medicine, ed. W. Coleman and F. L. Holmes, 139-78. Berkeley: Univ. of California Press.
23. Machamer, P., L. Darden, and C. F. Craver. 2000. Thinking about mechanisms. Philos Sci 67:1-25.
24. Müller, J. 1838. On the finer structure and the forms of morbid tumors. In Johannes Müller and the nineteenth-century origins of tumor cell theory, ed. L. J. Rather, P. Rather, and J. B. Frerichs, 56-150. Canton, MA: Science History Publications, 1986.
25. Nagel, T. 1998. Reductionism and antireductionism. In The limits of reductionism in biology, ed. G. R. Bock and J. A. Goode, 3-10. New York: John Wiley.
26. Pane, F., et al. 2002. BCR/ABL genes and leukemic phenotype: From molecular mechanisms to clinical correlations. Oncogene 21:8652-67.
27. Pinkel, D. 1987. Curing children of leukemia. Cancer 59:1683-91.
28. Pinkus, G. S. et al. 1997. Fascin, a sensitive new marker for Reed-Sternberg cells of Hodgkin's disease: Evidence for a dendritic or B cell variation? Am J Pathol 150:543-62.
29. Rather, L. J. 1971. The place of Virchow's Cellular Pathology in medical thought. Introd. to Cellular pathology as based upon physiological and pathological histology, by R. Virchow, trans. F. Chance, v-xxvii. New York: Dover Publications.
30. Rosenberg, A. 1997. Reductionism redux: Computing the embryo. Biol Philos 12:445-70.
31. Rothstein, W. G. 1987. American medical schools and the practice of medicine: A history. New York: Oxford Univ. Press.
32. Schechter, A. N. 1999. Medicine and biology are more than biomedicine. Nature 401:424.
33. Schmidt, C. A., and G. K. Przyblyski, 2001. What can we learn from leukemia as for the process of lineage commitment in hematopoiesis? Int Rev Immunol 20:107-15.
34. Stoker, M. 1975. Limits to oncology. Nature 254:547-48.
35. Stoker, M. 1980. New medicine and new biology. BMJ 281:1678-82.
36. Thomas, L. 1972. Aspects of biomedical science policy. Washington, DC: National Academy of Sciences, Institute of Medicine.
37. Thomson, A. L. 1973. Half a century of medical research. Vol. 1: Origins and policy of the Medical Research Council. London: HMSO.
38. Thomson, A. L. 1975. Half a century of medical research. Vol. 2: The programmes of the Medical Research Council. London: HMSO.
39. Van Brakel, J. 2000. The nature of chemical substances. In Of minds and molecules: New philosophical perspectives on chemistry, ed. N. Bhushan and S. Rosenfeld, 162-84. Oxford: Oxford Univ. Press.
40. Virchow, R. 1855. Cellular pathology. In Disease, life, and man. Selected essays by Rudolf Virchow, 71-101. Stanford: Stanford Univ. Press, 1958.
41. Virchow, R. 1858. Cellular pathology, as based upon physiological and pathological histology. New York: Dover Publications, 1971.
42. Wimsatt, W. 1984. Reductive explanation: A functional account. In Conceptual issues in evolutionary biology, ed. E. Sober, 477-508. Cambridge: MIT Press.
43. Wooldridge, D. E. 1965. Biomedical science and its administration. A study of the National Institutes of Health. Washington, DC: U.S. GPO.